Survival, safety, and prognostic factors for outcome with Regorafenib
in patients with metastatic colorectal cancer refractory to standard
therapies: results from a multicenter study (REBECCA) nested within a
compassionate use program
Antoine Adenis1,13*, Christelle de la Fouchardiere2, Bernard Paule3, Pascal Burtin4, David Tougeron5, Jennifer Wallet6,
Louis-Marie Dourthe7, Pierre-Luc Etienne8, Laurent Mineur9, Stéphanie Clisant10, Jean-Marc Phelip11, Andrew Kramar6
and Thierry Andre12
